e-Drug3D

2173

ELINZANETANT

INN
ELINZANETANT

cas 929046-33-3

CLASS

GENITO
NEUROKININ 1 (NK1) AND NEUROKININ 3 (NK3) RECEPTOR ANTAGONIST
TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS DUE TO MENOPAUSE

ROUTE (list)

ORAL

ATC code

G02CX07

PK parameters

F 52 PERCENT
Tmax 1 HOUR
VD 137 LITER
Cl 8.77 LITER / HOUR
PPB 99.7 PERCENT
t1/2 45 HOUR

Solubility

PRACTICALLY INSOLUBLE IN WATER

Target

TARGET NEUROKININ 1 (NK1)
NEUROKININ 3 (NK3)

DrugCentral

Download SDF file

Benzeneacetamide, N-[4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-hexahydro-7-(hydroxymethyl)pyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl]-N,alpha,alpha-trimethyl-3,5-bis(trifluoromethyl)-

Formula:
C33H35F7N4O3

Calculated chemical properties:

MW 668.65
NB_atoms 47
XLogP 6.06
PSA 67.264
NB_HD 1
NB_HA 7
fsp3 0.45
Lipinski(0=no;1=yes) 0

FDA
NDA 219469 (label) INN (ELINZANETANT) LYNKUET (BAYER HLTHCARE) APPROVAL= AP YEAR= 2025 NEWMOLECULARENTITY